Research ArticleTheranostics
Impact of 68Ga-PSMA-11 PET on Management in Patients with Biochemically Recurrent Prostate Cancer
Thomas A. Hope, Rahul Aggarwal, Bryant Chee, Dora Tao, Kirsten L. Greene, Matthew R. Cooperberg, Felix Feng, Albert Chang, Charles J. Ryan, Eric J. Small and Peter R. Carroll
Journal of Nuclear Medicine December 2017, 58 (12) 1956-1961; DOI: https://doi.org/10.2967/jnumed.117.192476
Thomas A. Hope
1Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California
2Department of Radiology, San Francisco VA Medical Center, San Francisco, California
3UCSF Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California
Rahul Aggarwal
3UCSF Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California
4Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, San Francisco, California
Bryant Chee
4Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, San Francisco, California
Dora Tao
1Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California
Kirsten L. Greene
5Department of Urology, University of California San Francisco, San Francisco, California; and
Matthew R. Cooperberg
3UCSF Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California
5Department of Urology, University of California San Francisco, San Francisco, California; and
Felix Feng
3UCSF Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California
6Department of Radiation Oncology, University of California San Francisco, San Francisco, California
Albert Chang
6Department of Radiation Oncology, University of California San Francisco, San Francisco, California
Charles J. Ryan
3UCSF Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California
4Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, San Francisco, California
Eric J. Small
3UCSF Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California
4Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, San Francisco, California
Peter R. Carroll
3UCSF Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California
5Department of Urology, University of California San Francisco, San Francisco, California; and
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 58, Issue 12
December 1, 2017
Impact of 68Ga-PSMA-11 PET on Management in Patients with Biochemically Recurrent Prostate Cancer
Thomas A. Hope, Rahul Aggarwal, Bryant Chee, Dora Tao, Kirsten L. Greene, Matthew R. Cooperberg, Felix Feng, Albert Chang, Charles J. Ryan, Eric J. Small, Peter R. Carroll
Journal of Nuclear Medicine Dec 2017, 58 (12) 1956-1961; DOI: 10.2967/jnumed.117.192476
Impact of 68Ga-PSMA-11 PET on Management in Patients with Biochemically Recurrent Prostate Cancer
Thomas A. Hope, Rahul Aggarwal, Bryant Chee, Dora Tao, Kirsten L. Greene, Matthew R. Cooperberg, Felix Feng, Albert Chang, Charles J. Ryan, Eric J. Small, Peter R. Carroll
Journal of Nuclear Medicine Dec 2017, 58 (12) 1956-1961; DOI: 10.2967/jnumed.117.192476
Jump to section
Related Articles
Cited By...
- Role of Prostate-Specific Membrane Antigen PET in Metastatic Prostate Cancer: We Have the Answers
- Diagnostic Performance and Clinical Impact of 68Ga-PSMA-11 PET/CT Imaging in Early Relapsed Prostate Cancer After Radical Therapy: A Prospective Multicenter Study (IAEA-PSMA Study)
- Detection Efficacy of 18F-rhPSMA-7.3 PET/CT and Impact on Management in Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy and Before Potential Salvage Treatment
- A Phase II, Open-Label Study to Assess Safety and Management Change Using 68Ga-THP PSMA PET/CT in Patients with High-Risk Primary Prostate Cancer or Biochemical Recurrence After Radical Treatment: The PRONOUNCED Study
- Rational Linker Design to Accelerate Excretion and Reduce Background Uptake of Peptidomimetic PSMA-Targeting Hybrid Molecules
- Darolutamide Potentiates the Antitumor Efficacy of a PSMA-targeted Thorium-227 Conjugate by a Dual Mode of Action in Prostate Cancer Models
- Cytoplasmic Localization of Prostate-Specific Membrane Antigen Inhibitors May Confer Advantages for Targeted Cancer Therapies
- Impact of 68Ga-PSMA-11 PET on the Management of Recurrent Prostate Cancer in a Prospective Single-Arm Clinical Trial
- Factors Predicting Metastatic Disease in 68Ga-PSMA-11 PET-Positive Osseous Lesions in Prostate Cancer
- 3-Year Freedom from Progression After 68Ga-PSMA PET/CT-Triaged Management in Men with Biochemical Recurrence After Radical Prostatectomy: Results of a Prospective Multicenter Trial
- 18F-rhPSMA-7 PET for the Detection of Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy
- Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer
- A Prospective Study on 18F-DCFPyL PSMA PET/CT Imaging in Biochemical Recurrence of Prostate Cancer
- Intention-to-Treat Analysis of 68Ga-PSMA and 11C-Choline PET/CT Versus CT for Prostate Cancer Recurrence After Surgery
- Bridging the Imaging Gap: PSMA PET/CT Has a High Impact on Treatment Planning in Prostate Cancer Patients with Biochemical Recurrence--A Narrative Review of the Literature
- Impact of 68Ga-PSMA PET/CT on the Radiotherapeutic Approach to Prostate Cancer in Comparison to CT: A Retrospective Analysis
- Prospective, Multisite, International Comparison of 18F-Fluoromethylcholine PET/CT, Multiparametric MRI, and 68Ga-HBED-CC PSMA-11 PET/CT in Men with High-Risk Features and Biochemical Failure After Radical Prostatectomy: Clinical Performance and Patient Outcomes
- Metaanalysis of 68Ga-PSMA-11 PET Accuracy for the Detection of Prostate Cancer Validated by Histopathology
- Outcome After PSMA PET/CT-Based Salvage Radiotherapy in Patients with Biochemical Recurrence After Radical Prostatectomy: A 2-Institution Retrospective Analysis
- EBONI: A Tool for Automated Quantification of Bone Metastasis Load in PSMA PET/CT
- Impact of 68Ga-PSMA-11 PET/CT on the Management of Prostate Cancer Patients with Biochemical Recurrence